MSK ROI: De-Risking Digital Health Investments for Employers

Digital musculoskeletal (MSK) programs have proliferated, promising significant relief for a major category of employer health spend. Yet, the financial claims associated with these solutions are under increasing scrutiny, prompting a critical need for a structured framework to evaluate their true return on investment. Without a clear methodology to separate genuine medical cost substitution from mere wellness engagement, employers and investors risk misallocating resources on interventions that lack demonstrable financial performance.

The Imperative for Independent Health Technology Assessment

The digital health field is crowded, and MSK solutions are no exception. Many platforms tout impressive engagement metrics or anecdotal success stories, but for value-based care arrangements, the bar is set much higher: demonstrable, peer-reviewed outcomes data. This is precisely why independent health technology assessment (HTA) reports are becoming indispensable. These reports provide an objective lens, verifying cost-effectiveness metrics and medical spend reduction figures, alongside clinical outcome measures for pain reduction and surgery avoidance. The Peterson Health Technology Institute (PHTI) has emerged as a critical authority in this space, conducting rigorous evaluations of health technology’s clinical and economic impact. Their assessments, particularly concerning digital MSK solutions, offer a vital benchmark for self-insured employer benefit managers, benefits consultants, and digital health VCs. The PHTI’s work highlights the distinction between programs that offer a genuine substitution for traditional, often more expensive, care pathways and those that primarily deliver engagement without significant medical cost savings.

Deconstructing Economic Claims: PHTI’s Findings on Digital MSK

The PHTI’s assessment of digital MSK solutions provides a critical, independent evaluation of economic and clinical performance across the market. While PHTI rigorously scrutinizes claims of medical cost reduction, its June 2024 report (updated October 2024) found that many virtual MSK solutions, particularly physical therapist-guided ones, deliver clinically meaningful improvements in pain and function comparable to in-person physical therapy. These solutions also demonstrate the potential to reduce healthcare spending. For instance, the report estimates that if 25% of in-person physical therapy users with low back pain shifted to these platforms at a price of $995 per year, annual savings could total approximately $4.4 million per one million commercially insured individuals. This is a critical distinction for value-based care, where financial performance is paramount. When evaluating programs like Hinge Health, which provides virtual physical therapy and joint care, and Sword Health, which delivers digital physical therapy solutions, the PHTI emphasizes the necessity of strong, independently verified data. The PHTI’s analysis dissects the methodologies used by these companies to calculate ROI, and while it highlights the importance of ensuring claimed savings are directly attributable to medical cost substitution rather than being overstated or a reallocation of existing spend, its overall findings for physical therapist-guided solutions are positive regarding their potential for clinical benefits and economic impact. This distinction is critical for value-based care, where demonstrable financial performance is paramount PHTI digital MSK assessment report. A key takeaway from such independent assessments is the importance of distinguishing between “cost avoidance” and “cost reduction.” Many digital MSK programs claim to avoid costs by preventing surgeries or emergency room visits. However, proving that these events would have occurred in the absence of the digital intervention requires sophisticated control groups and long-term follow-up, which are often lacking in vendor-provided studies. The PHTI’s methodology, by contrast, focuses on verifiable medical claims data and strong statistical analysis to determine actual reductions in medical spend.

A Framework for Evaluating Digital MSK Platforms

Based on the insights from independent HTAs, we propose a framework for assessing digital MSK platforms, focusing on true substitution value and financial performance. This framework moves beyond superficial engagement metrics to scrutinize the core drivers of value in a value-based care context.

1. Verified Medical Cost Reduction

The foundation of any value-based AI health solution is its ability to reduce medical spend. This must be substantiated by:

• Independent Claims Analysis: Require vendors to provide data that has been analyzed by a third-party actuarial firm or an independent HTA body like PHTI, demonstrating significant and sustained reductions in MSK-related medical claims. This includes reductions in specialist visits, imaging, injections, and surgeries.
• Net Savings Calculation: Scrutinize the methodology for calculating net savings. Ensure that the program’s cost is fully accounted for and that any claimed savings are not simply a reallocation of existing spend or an artifact of selection bias.
• Longitudinal Data: Demand evidence of cost reductions over a meaningful period (e.g., 2-3 years) to ensure sustained impact and rule out short-term fluctuations.

2. Clinical Outcomes with Economic Impact

Clinical efficacy is important, but it must translate into economic value.

• Validated Pain Reduction: Look for studies using standardized, validated pain scales (e.g., VAS, ODI) with statistically significant and clinically meaningful improvements, ideally compared to a control group.
• Surgery Avoidance Supported by Data: Claims of surgery avoidance must be backed by evidence that patients enrolled in the program would have otherwise undergone surgery. This requires careful consideration of patient stratification and appropriate comparison groups. The PHTI report often highlights the difficulty in substantiating these claims without strong methodologies.
• Functional Improvement: Evidence of improved functional capacity (e.g., ability to perform daily activities, return to work) can indirectly support economic benefits by reducing disability claims and improving productivity.

3. Data Quality and Transparency

The integrity of the data is paramount for trust and accurate evaluation.

• Real-World Evidence (RWE): While randomized controlled trials (RCTs) are the gold standard for clinical efficacy, RWE derived from claims data and electronic health records is essential for demonstrating real-world financial performance in diverse populations.
• HIPAA Compliance and Data Security: Ensure the platform adheres to stringent data privacy and security standards such as HIPAA, HITRUST, or SOC 2 Type II, safeguarding sensitive patient information. HITRUST certification requirements
• Transparency in Methodology: Vendors must be transparent about their data collection, analysis methods, and assumptions used in ROI calculations. Any proprietary algorithms or data moats should be explained in sufficient detail to allow for independent assessment.

4. Scalability and Integration

A program’s ability to scale and integrate smoothly into existing healthcare ecosystems impacts its long-term value.

• Interoperability: The platform should demonstrate clear pathways for integrating with existing EHR systems, claims processors, and other health benefits platforms to simplify data exchange and reduce administrative burden.
• User Engagement and Adherence: High engagement is necessary but not sufficient. Focus on adherence to the clinical protocols within the program, as this is more directly linked to outcomes.

Methodology and Source Note

This framework is developed through an analysis of independent health technology assessment reports, specifically drawing heavily from the methodologies and findings presented by the Peterson Health Technology Institute (PHTI) regarding digital MSK solutions. The PHTI’s rigorous approach to evaluating both the clinical efficacy and economic claims of health technologies is the authoritative node for our recommendations. Our intention is to provide self-insured employer benefit managers, benefits consultants, and digital health VCs with a strong, evidence-based lens through which to assess digital MSK platforms, ensuring that investments yield verifiable value-based outcomes rather than unproven promises. This approach aligns directly with the core mission of Value-Based Health AI: advocating for tools with peer-reviewed outcomes data as the sole participants in value-based care arrangements. Peterson Health Technology Institute homepage